A tumour risk linked to some pluripotent cells — avoided by characterised, regulated protocols.
A tumour formed when pluripotent or poorly differentiated stem cells develop uncontrollably into multiple cell types (hair, bone, fat mixed chaotically). It's the main theoretical risk of pluripotent stem-cell therapy. Teratomas are rare in clinical practice with differentiated cells (bone-marrow MSCs, cord blood), but the risk is non-zero if pluripotent cells aren't fully controlled. Ask clinics whether they use pluripotent cells and, if so, what safety monitoring they employ (imaging at 3, 6, 12 months post-injection) to detect early tumour development. Reputable clinics avoid pluripotent cells for clinical work or apply rigorous differentiation protocols.
Medicina regenerativa certificada GMP en el corazón de la UE — desde 3.000–8.000 €, una fracción de los precios de EE. UU. o Alemania. Protocolos personalizados para pacientes de más de 50 países.
Evaluación médica gratuita